MTAA / Expert Witness Directory BETA
Search AI Match ← MTAA
← Back to search
Joshua Sharlin, Ph.D.
Specialty not on record · TX
3
Total cases
3
Plaintiff-side
0
Defense-side
0
Daubert survived
0
Daubert excluded

About

**EXPERT INTELLIGENCE PROFILE: Joshua Sharlin, Ph.D.** Joshua Sharlin, Ph.D., presents a significant intelligence gap for litigation teams. His credentials, institutional affiliation, and specific area of expertise remain undocumented in available records, creating immediate concerns about transparency and qualification verification. Without clear specialty documentation, his methodology and analytical approach cannot be assessed, which poses substantial risks for both retention and opposition strategy. Sharlin's courtroom record shows exclusive plaintiff-side work, appearing three times in Villarreal v. Taro Pharmaceuticals in the Southern District of Texas in 2017—though the duplicate entries suggest potential data anomalies rather than multiple distinct engagements. This pharmaceutical litigation focus suggests potential expertise in drug safety, regulatory compliance, or related pharmaceutical sciences, but the lack of specialty confirmation makes this speculative. Notably, despite his testimony history, no Daubert challenges appear on record, which could indicate either uncontroversial opinions or limited judicial scrutiny of his qualifications. For plaintiff attorneys, Sharlin represents a high-risk proposition due to the credential verification gap. His consistent plaintiff alignment suggests philosophical compatibility, but the absence of documented expertise creates significant Daubert vulnerability—opposing counsel will likely challenge his qualifications immediately. The lack of institutional affiliation raises additional credibility concerns that could undermine jury perception. If considering retention, demand comprehensive CV verification and specialty documentation before engagement. If opposing Sharlin, focus Daubert challenges on foundational qualifications and demand detailed credential substantiation, as the current record provides insufficient basis for expert qualification under Federal Rule 702.

Daubert Record 0 on record

No Daubert challenges on record.

Case Appearances from PACER filings

Villarreal v. Taro Pharmaceuticals, U.S.A., Inc.
plaintiff District Court, S.D. Texas 2017-02-01 View filing →
DESIGNATION OF EXPERT WITNESS LIST by Mary Eloisa Villarreal, filed. (Attachments: # 1 Exhibit Rule 26 Expert Report of
Villarreal v. Taro Pharmaceuticals, U.S.A., Inc.
plaintiff District Court, S.D. Texas 2017-02-01 View filing →
DESIGNATION OF EXPERT WITNESS LIST by Mary Eloisa Villarreal, filed. (Attachments: # 1 Exhibit Rule 26 Expert Report of
Villarreal v. Taro Pharmaceuticals, U.S.A., Inc.
plaintiff District Court, S.D. Texas 2017-02-01 View filing →
DESIGNATION OF EXPERT WITNESS LIST by Mary Eloisa Villarreal, filed. (Attachments: # 1 Exhibit Rule 26 Expert Report of
All data sourced from public PACER court records via CourtListener. Profile last updated based on available filings. Expert witnesses may claim this profile to add contact information and availability.